NDATOPICALCREAM
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
RHOFADE (oxymetazoline hydrochloride) by PharmaIN. Approved for rosacea. First approved in 2017.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RHOFADE is a topical cream formulation of oxymetazoline hydrochloride, an alpha-adrenergic agonist indicated for rosacea and acquired blepharophimosis. It works by constricting blood vessels in the skin to reduce facial erythema and eyelid drooping. The product targets inflammatory and vascular symptoms associated with these dermatological conditions.
$3MPart D
PeakStable
9.1 years to LOEAt peak lifecycle with modest $3M spending and stable claim volume; brand team likely focused on market maintenance and patient retention rather than aggressive expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (1)
A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
Started Apr 2019
1,105 enrolled
Rosacea
Career Relevance
No linked job postings identified for RHOFADE; career opportunity likely embedded in broader PharmaIN dermatology or specialty care teams. Commercial roles (brand manager, sales, marketing) would focus on maintaining peak-stage performance and managing upcoming generic erosion.
Worked on RHOFADE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.